Connecticut Administrative Code › Title 19a - Public Health and Well-being › 589 - Aids Related Testing and Medical Information and Confidentiality › Section 19a-589-1 - Definitions

Current through July 10, 2024
As used in sections 19a-589-1 through
				19a-589-3
				inclusive as follows:
(a) "AIDS" means
			 acquired immune deficiency syndrome, as defined by the Centers for Disease
			 Control of the United States Public Health Service;
(b) "Confidential HIV-related information"
			 means any information pertaining to the protected individual or obtained
			 pursuant to a release of confidential HIV related information, concerning
			 whether a person has been counseled regarding HIV infection, has been the
			 subject of an HIV-related test, or has HIV infection, HIV-related illness or
			 AIDS, or information which identifies or reasonably could identify a person as
			 having one or more of such conditions, including information pertaining to such
			 individual's partners;
(c)
			 "Exposure evaluation group" means at least three impartial health care
			 providers, at least one of whom shall be a physician, designated by the chief
			 administrator of a health facility, correctional facility or other institution
			 to determine if a health care or other worker has been involved in a
			 significant exposure. No member of the group shall be directly involved in the
			 exposure;
(d) "FDA" means the
			 United States Food and Drug Administration;
(e) "Health care provider" means any
			 physician, dentist, nurse, provider of services for the mentally ill or persons
			 with mental retardation, or other person involved in providing medical,
			 nursing, counseling, or other health care, substance abuse or mental health
			 service, including such services associated with, or under contract to, a
			 health maintenance organization or medical services plan;
(f) "Health facility" means an institution,
			 as defined in section
			 19a-490
			 of the general statutes, blood bank, blood center, sperm bank, organ or tissue
			 bank, clinical laboratory or facility providing care or treatment to the
			 mentally ill or persons with mental retardation or a facility for the treatment
			 of substance abuse;
(g) "HIV
			 infection" means infection with the human immunodeficiency virus or any other
			 related virus identified as a probable causative agent of AIDS;
(h) "HIV-related illness" means any illness
			 that may result from or may be associated with HIV infection;
(i) "HIV-related test" means any laboratory
			 test or series of tests for any virus, antibody, antigen or etiologic agent
			 whatsoever thought to cause or indicate the presence of HIV
			 infection;
(j) "Meaningful
			 immediate action" means any one of:
(1) the
			 following actions related to drug therapy/prophylaxis-
(A) to start taking a drug that has been FDA
			 approved for treatment of HIV related illness or has been approved for
			 investigational use in humans for treatment of HIV-related illness, or to stop
			 taking such drug if the source of the exposure tests negative for HIV, provided
			 the drug:
(i) may prevent seroconversion in
			 persons who have been exposed to HIV, or
(ii) may limit or ameliorate the effects of
			 HIV infection,